NeurAxis, Inc. (NRXS) Stock Price & Analysis
NeurAxis, Inc. (NRXS) closed at USD 7.74 on Thursday, October 15, 2026, up 18.53% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.53; the Oct 15, 2026 session ranged USD 6.8–7.81 on volume of 1,124,658 shares. Market capitalization is $97.20M, with a 52-week range of USD 2.21–9.33 (ASE). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NRXS.md
Key facts (NRXS)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 11 (range 9–13).
- Total return with dividends: 1Y +146.5% vs S&P 500 +18.1%; 5Y +25.9% vs S&P 500 +85.1%.
Analysts (NRXS)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 11 (low 9, high 13).
Total return (dividends reinvested) (NRXS)
| 1Y (from 2025-10-16) | 5Y (from 2023-08-07) | |
|---|---|---|
| Total return | +146.5% | +25.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +147.3% | +7.5% |
| Volatility (annualized) | 75.9% | 79.0% |
| Max drawdown | -39.5% (Oct 2025→Nov 2025) | -74.0% (Aug 2023→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 7.74 |
|---|---|
| Change | ▲ 18.53% (up) |
| Previous Close | USD 6.53 |
| Open | USD 6.87 |
| Day Range | USD 6.8 – 7.81 |
| 52-Week Range | USD 2.21 – 9.33 |
| Volume | 1,124,658 shares |
| Market Cap | $97.20M |
| Exchange | ASE |
Technical Analysis (NRXS)
Nexqual's technical model rates NRXS "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.42 (neutral) |
| vs SMA50 | Above (USD 6.6) |
| MACD | 0.08 (positive) |
Analyst Ratings (NRXS)
Wall Street analysts rate NRXS "Buy" based on 2 analysts, with a mean price target of USD 11 (range USD 9–13), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 11 |
| High Target | USD 13 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (NRXS)
| EPS Estimate | USD -0.21 |
|---|---|
| Revenue Estimate | $2.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.19 vs est -0.32 ▲ beat |
| 2025-12-31 | USD -0.1 vs est -0.22 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.2 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (NRXS)
| Total Revenue | $5.32M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +115.70% |
| Gross Margin | +85.56% |
| Operating Margin | -110.16% |
| Profit Margin | -144.44% |
| ROE | -139.76% |
| Debt / Equity | 0.04 |
| Current Ratio | 3.04 |
| Total Cash | $8.32M |
| Total Debt | $279,392 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (NRXS)
Nexqual rates NeurAxis, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +116% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $8M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M (TTM) |
| Efficiency | Critical — ROE -140%, ROA -56.2% |
Ownership (NRXS)
| Insider Ownership | +25.36% |
|---|---|
| Institutional Ownership | +28.44% |
| Shares Outstanding | 12.56M |
| Float | 8.33M |
| Short % of Float | +3.79% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (NRXS)
NeurAxis, Inc. is led by Brian Carrico (age 43), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Director | Brian Carrico (age 43) |
|---|---|
| Chief Financial Officer | Timothy Robert Henrichs (age 52) |
| Founder, Director of Innovation & Director | Christopher Robin Brown D.D.S. (age 71) |
| Vice President of Sales | Ryan Kuhlman |
| Vice President of Marketing | Trisha Baumgardt |
Major Backers & Investors (NRXS)
Notable institutional backers of NeurAxis, Inc. include AIGH Capital Management LLC, Rosalind Advisors, Inc., Money Concepts Capital Corporation, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 4.14% |
| Rosalind Advisors, Inc. | 4.05% |
| Money Concepts Capital Corporation | 1.82% |
| Renaissance Technologies | 1.35% |
| Marshall Wace LLP | 1.03% |
| Parsons Capital Management Inc/RI | 0.94% |
| Panoramic Capital, LLC | 0.92% |
| Citadel | 0.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.32% |
| Geode Capital | 0.77% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt